These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

500 related items for PubMed ID: 19283693

  • 21. Deletion of fusion peptide or destabilization of fusion core of HIV gp41 enhances antigenicity and immunogenicity of 4E10 epitope.
    Li J, Chen X, Jiang S, Chen YH.
    Biochem Biophys Res Commun; 2008 Nov 07; 376(1):60-4. PubMed ID: 18762167
    [Abstract] [Full Text] [Related]

  • 22. Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions.
    Dennison SM, Stewart SM, Stempel KC, Liao HX, Haynes BF, Alam SM.
    J Virol; 2009 Oct 07; 83(19):10211-23. PubMed ID: 19640992
    [Abstract] [Full Text] [Related]

  • 23. The broadly neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5.
    Huarte N, Lorizate M, Maeso R, Kunert R, Arranz R, Valpuesta JM, Nieva JL.
    J Virol; 2008 Sep 07; 82(18):8986-96. PubMed ID: 18596094
    [Abstract] [Full Text] [Related]

  • 24. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies.
    Yang G, Holl TM, Liu Y, Li Y, Lu X, Nicely NI, Kepler TB, Alam SM, Liao HX, Cain DW, Spicer L, VandeBerg JL, Haynes BF, Kelsoe G.
    J Exp Med; 2013 Feb 11; 210(2):241-56. PubMed ID: 23359068
    [Abstract] [Full Text] [Related]

  • 25. Structural constraints imposed by the conserved fusion peptide on the HIV-1 gp41 epitope recognized by the broadly neutralizing antibody 2F5.
    de la Arada I, Julien JP, de la Torre BG, Huarte N, Andreu D, Pai EF, Arrondo JL, Nieva JL.
    J Phys Chem B; 2009 Oct 15; 113(41):13626-37. PubMed ID: 19754136
    [Abstract] [Full Text] [Related]

  • 26. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.
    Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, Katinger H.
    AIDS Res Hum Retroviruses; 2001 Dec 10; 17(18):1757-65. PubMed ID: 11788027
    [Abstract] [Full Text] [Related]

  • 27. Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes.
    Matyas GR, Wieczorek L, Beck Z, Ochsenbauer-Jambor C, Kappes JC, Michael NL, Polonis VR, Alving CR.
    AIDS; 2009 Oct 23; 23(16):2069-77. PubMed ID: 19710597
    [Abstract] [Full Text] [Related]

  • 28. Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function.
    Guenaga J, Wyatt RT.
    PLoS Pathog; 2012 Oct 23; 8(7):e1002806. PubMed ID: 22829767
    [Abstract] [Full Text] [Related]

  • 29. Structure-affinity relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing monoclonal antibody 2F5: effects of side-chain and backbone modifications and conformational constraints.
    Tian Y, Ramesh CV, Ma X, Naqvi S, Patel T, Cenizal T, Tiscione M, Diaz K, Crea T, Arnold E, Arnold GF, Taylor JW.
    J Pept Res; 2002 Jun 23; 59(6):264-76. PubMed ID: 12010517
    [Abstract] [Full Text] [Related]

  • 30. Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution.
    Shen X, Dennison SM, Liu P, Gao F, Jaeger F, Montefiori DC, Verkoczy L, Haynes BF, Alam SM, Tomaras GD.
    Proc Natl Acad Sci U S A; 2010 Mar 30; 107(13):5972-7. PubMed ID: 20231447
    [Abstract] [Full Text] [Related]

  • 31. Progress towards the development of a HIV-1 gp41-directed vaccine.
    McGaughey GB, Barbato G, Bianchi E, Freidinger RM, Garsky VM, Hurni WM, Joyce JG, Liang X, Miller MD, Pessi A, Shiver JW, Bogusky MJ.
    Curr HIV Res; 2004 Apr 30; 2(2):193-204. PubMed ID: 15078183
    [Abstract] [Full Text] [Related]

  • 32. The neutralizing epitope ELDKWA on HIV-1 gp41: genetic variability and antigenicity.
    Dong XN, Wu Y, Chen YH.
    Immunol Lett; 2005 Oct 15; 101(1):81-6. PubMed ID: 15951025
    [Abstract] [Full Text] [Related]

  • 33. Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody.
    Brunel FM, Zwick MB, Cardoso RM, Nelson JD, Wilson IA, Burton DR, Dawson PE.
    J Virol; 2006 Feb 15; 80(4):1680-7. PubMed ID: 16439525
    [Abstract] [Full Text] [Related]

  • 34. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.
    Ofek G, Tang M, Sambor A, Katinger H, Mascola JR, Wyatt R, Kwong PD.
    J Virol; 2004 Oct 15; 78(19):10724-37. PubMed ID: 15367639
    [Abstract] [Full Text] [Related]

  • 35. N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies.
    Li D, Liu J, Zhang L, Xu T, Chen J, Wang L, Zhao Q.
    Virol Sin; 2015 Dec 15; 30(6):449-56. PubMed ID: 26715302
    [Abstract] [Full Text] [Related]

  • 36. Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10.
    Chen Y, Zhang J, Hwang KK, Bouton-Verville H, Xia SM, Newman A, Ouyang YB, Haynes BF, Verkoczy L.
    J Immunol; 2013 Aug 01; 191(3):1260-75. PubMed ID: 23825311
    [Abstract] [Full Text] [Related]

  • 37. [Immunogenetic properties of peptides mimicking a human immunodeficiency virus gp41 (HIV-1) epitope recognized by virus-neutralizing antibody 2F5].
    Tumanova OIu, Kuvshinov VN, Orlovskaia IA, Proniaeva TR, Pokrovskiĭ AG, Il'ichev AA, Sandakhchiev LS.
    Mol Biol (Mosk); 2003 Aug 01; 37(3):556-60. PubMed ID: 12815965
    [Abstract] [Full Text] [Related]

  • 38. Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment.
    Luo M, Yuan F, Liu Y, Jiang S, Song X, Jiang P, Yin X, Ding M, Deng H.
    Vaccine; 2006 Jan 23; 24(4):435-42. PubMed ID: 16143433
    [Abstract] [Full Text] [Related]

  • 39. Multifaceted consequences of anti-gp41 monoclonal antibody 2F5 binding to HIV type 1 virions.
    Neurath AR, Strick N, Lin K, Jiang S.
    AIDS Res Hum Retroviruses; 1995 Jun 23; 11(6):687-96. PubMed ID: 7576928
    [Abstract] [Full Text] [Related]

  • 40. Recognition of membrane-bound fusion-peptide/MPER complexes by the HIV-1 neutralizing 2F5 antibody: implications for anti-2F5 immunogenicity.
    Huarte N, Araujo A, Arranz R, Lorizate M, Quendler H, Kunert R, Valpuesta JM, Nieva JL.
    PLoS One; 2012 Jun 23; 7(12):e52740. PubMed ID: 23285173
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.